University Hospital and UW Health Clinics

Madison, Wisconsin 53792

4 studies enrolling now · 12 studies all time

What they study most

Achondroplasia, Brain Edema, Carcinoma, Non-Small-Cell Lung, Cystic Fibrosis, Esophagitis, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Lyme Disease, Progressive Pulmonary Fibrosis, Spinal Muscular Atrophy, Stroke, Acute

Studies at this site

• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer — Recruiting now
• Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) — Recruiting now
• Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease — Enrolling by invitation
• A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy — Running, not enrolling
• Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years — Stopped early
• An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) — Completed
• Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2 — Completed
• Extension Study of Infigratinib in Children With Achondroplasia (ACH) — Enrolling by invitation
• Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction — Stopped early
• A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation — Completed
• A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies — Withdrawn before enrolling
• Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis — Completed